News and Media
Imophoron Announces Publication of Scientific Paper Highlighting the Ability of ADDomer to Combat Viral Infections.
Avenir Light is a clean and stylish font favored by designers. It's easy on the eyes and a great go-to font for titles, paragraphs & more.
Imophoron announces a new investment from Global Brain as part of a £2.4m extension to its Seed financing round.
Imophoron announces a strategic process development partnership with eXmoor pharma for its ADDomer RSV vaccine candidate.
Imophoron appoints Richard Bungay as Chief Executive Officer with Founding CEO Fred Garzoni to become Chief Scientific Officer.
Imophoron co-founders, Fred Garzoni and Imre Berger announce the establishment of the company's Scientific Advisory Board (SAB). The SAB consists of internationally renowned experts in the vaccine industry, public health and policymaking.
Imre Berger, Co-founder of Imophoron, Professor of Biochemistry and Chemistry and Director of Bristol’s Max Planck Centre for Minimal Biology has been elected as a Fellow of the Academy of Medical Sciences (FMedSci) for his outstanding contributions to biomedical science and notable discoveries during the COVID-19 pandemic.
Imophoron CEO, Fred Garzoni, is announced as among the 2022 Franco-British Young Leader cohort. Discover what the role and mission of the Franco-British Young Leaders is and the impact they hope to have on business relations.
Insight into Imophoron's CEO, Fred Garzoni, and his journey as an entrepreneur and his vision between French and UK start-up ecosystem. Written by Arthur Belaud, Deputy Attaché for Science and Innovation Higher Education, Research and Innovation Department at the French Embassy in London.
Imophoron's CEO Fred Garzoni and Jonathan Hare, Head of Immunology, discuss the vaccine and treatment pipeline for COVID 19 and what the future holds for Imophoron.
The Science Creates team interviews Imophoron's CEO, Fred Garzoni, to gain insight into his journey as an entrepreneur and how he brought the concept of his company from France and made it a reality in Bristol.
Imophoron, the developer of a novel, next generation rapid-response vaccine platform, ADDomer, to combat present and future infectious diseases, announces it has secured GBP 4 million in an oversubscribed fundraising round.
Vaccine Pioneers Imophoron Close £4m Investment Round with Science Creates Ventures
Press release to announce Imophoron successfully securing £4m investment.
South West 2021 42 under 42 Members
Fred Garzoni, CEO of Imophoron, is listed as one of 42 profiles of young entrepreneurs and business leaders under 42 years old in the south west of England one Insidermedia's ones to watch list.
Business Leader journal nominate the top 32 'business heroes' of COVID-19 which features Imophoron's Fred Garzoni and co-founder Imre Berger.
Shedding light on Imphoron's work on the Spike protein of SARS-CoV2 which was published in Science, in collaboration with Oracle.
Technology of Business Editor at the BBC interviews Imophoron's CEO, Fred Garzoni, to discuss how high-level technology is changing the landscape of vaccine manufacturing.
Highlighting Imophoron's work on the ADDomer platform and how this ground-breaking technology may change the vaccine world.